News


Browse the most recent updates on breakthroughs, research, member activities, and treatment options. Stay informed with the latest advancements shaping the landscape of lung cancer care in Europe and globally.

  • 28TH NOVEMBER: CURRENT CHALLENGES IN CLINICAL TRIALS


    Lung Cancer Europe will hold an event on 28th November at the EU Parliament to highlight the current challenges in clinical trials across Europe Within the…

    Read More

  • NOVEMBER IS LUNG CANCER AWARENESS MONTH


    According to Globocan 2018, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause…

    Read More

  • BEING HEARD OVER THE NOISE


    LuCE president, Stefania Vallone provided an insight analysis on “Being heard over the noise: The patient viewpoint” during #ESMO2018. She emphasized the role can patients…

    Read More

  • LUCE STAND AT ESMO 2018


    We invite all interested ESMO members to visit us @LuCE booth located in the society village at ESMO 2018 in Munich. Name: LuCEHall: B1Stand: PA 8 LuCE…

    Read More

  • default image

    NEW GLOBOCAN STATISTICS PLACED LUNG CANCER AS THE MOST FREQUENT CANCER AND THE LEADING CAUSE OF CANCER DEATH AMONG MALES


    According to tthe new statistics, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6 % of the total cases) and the…

    Read More

  • default image

    #WCLC2018 CONCLUSIONS – STRATEGIES TO MAXIMIZE THE CLINICAL BENEFIT OF EGFR TKIS IN ADVANCED NSCLC


    During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC. Apply expert recommendations for frontline therapy for…

    Read More

  • #WCLC2018 CONCLUSIONS – NELSON STUDY SHOWS CT SCREENING FOR NODULE VOLUME MANAGEMENT REDUCES LUNG CANCER MORTALITY BY 26 PERCENT IN MEN


    During the World Congress on Lung Cancer held this year in Toronto, Canada were presented the findings of NELSON study. These demonstrate that the use…

    Read More

  • LUNG CANCER EUROPE IS GROWING STRONGER


    Starting September, Alfonso Aguarón (second from left) is LuCE’s new project manager. He has extensive experience in patient advocacy field as Hodgkin’s Lymphoma survivor. This…

    Read More

  • NEW ESMO TUMOUR DNA SCALE HELPS MATCH PATIENTS WITH CANCER TO OPTIMAL TARGETED MEDICINES


    A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe…

    Read More